ATE549313T1 - Verbindungen mit antitumorwirkung - Google Patents

Verbindungen mit antitumorwirkung

Info

Publication number
ATE549313T1
ATE549313T1 AT08865009T AT08865009T ATE549313T1 AT E549313 T1 ATE549313 T1 AT E549313T1 AT 08865009 T AT08865009 T AT 08865009T AT 08865009 T AT08865009 T AT 08865009T AT E549313 T1 ATE549313 T1 AT E549313T1
Authority
AT
Austria
Prior art keywords
compounds
antitumor effects
antitumor
cancer
compound
Prior art date
Application number
AT08865009T
Other languages
English (en)
Inventor
Vicente Alberto Rodroeguez
Garcoea-Ibarrola Maria Garranzo
Perez Carmen Murcia
Sancho Francisco Sanchez
Marchante Maria Cuevas
Urbano Cristina Mateo
Juarez Isabel Digan
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Application granted granted Critical
Publication of ATE549313T1 publication Critical patent/ATE549313T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
AT08865009T 2007-12-20 2008-12-19 Verbindungen mit antitumorwirkung ATE549313T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07123882 2007-12-20
PCT/EP2008/068065 WO2009080769A1 (en) 2007-12-20 2008-12-19 Antitumoral compounds

Publications (1)

Publication Number Publication Date
ATE549313T1 true ATE549313T1 (de) 2012-03-15

Family

ID=40580474

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08865009T ATE549313T1 (de) 2007-12-20 2008-12-19 Verbindungen mit antitumorwirkung

Country Status (26)

Country Link
US (4) US8710264B2 (de)
EP (3) EP2231633B1 (de)
JP (3) JP5727228B2 (de)
KR (3) KR101639772B1 (de)
CN (4) CN101903367B (de)
AT (1) ATE549313T1 (de)
AU (2) AU2008341670B2 (de)
BR (2) BRPI0821116B8 (de)
CA (2) CA2710087C (de)
CY (1) CY1117245T1 (de)
DK (2) DK2231633T3 (de)
ES (3) ES2578606T3 (de)
HR (2) HRP20120464T1 (de)
IL (3) IL206396A (de)
MX (2) MX2010006795A (de)
MY (3) MY155342A (de)
NZ (3) NZ586012A (de)
PL (2) PL2231590T3 (de)
PT (2) PT2231590E (de)
RS (2) RS52343B (de)
RU (3) RU2489429C2 (de)
SG (2) SG170778A1 (de)
SI (2) SI2231633T1 (de)
UA (3) UA106967C2 (de)
WO (2) WO2009080769A1 (de)
ZA (3) ZA201004017B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0821116B8 (pt) 2007-12-20 2021-05-25 Pharma Mar Sa composto, composição farmacêutica que o contem, uso deste e processo para a preparação do mesmo
US9856196B2 (en) 2012-01-05 2018-01-02 Kao Corporation Agent for reduction of sensory irritation
EA029361B1 (ru) 2013-04-16 2018-03-30 Идорсиа Фармасьютиклз Лтд Антибактериальные биароматические производные
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
CN108467378A (zh) * 2017-02-23 2018-08-31 复旦大学 一种二氢吡喃酮类化合物及其制备方法和用途
US11332480B2 (en) 2017-04-27 2022-05-17 Pharma Mar, S.A. Antitumoral compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US4855086A (en) * 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
JPS61109717A (ja) * 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
CA2098702A1 (en) * 1990-12-28 1992-06-29 James C. Powers Peptide ketoamides, ketoacids, and ketoesters
JPH0539283A (ja) * 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
ZA938019B (en) 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
US5523456A (en) * 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5681847A (en) * 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
US5834506A (en) 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
US6380400B1 (en) 1998-09-11 2002-04-30 Victor Fedij Methods of making dihydropyrone HIV protease inhibitors
NZ510013A (en) 1998-09-11 2003-11-28 Warner Lambert Co Dihydropyrones with selected heterocycles replacing the phenyls bearing polar substituents used as HIV protease inhibitors
WO2001074355A1 (en) * 2000-04-04 2001-10-11 Novartis Ag Method for treating cells resistant to antineoplastic agents
NZ550185A (en) * 2002-03-04 2008-10-31 Merck Hdac Res Llc Methods of inducing terminal differentiation Methods of inducing terminal differentiation
CN1856486A (zh) * 2003-07-25 2006-11-01 诺瓦提斯公司 取代的内酰胺和它们作为抗癌剂的用途
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
RU2006142690A (ru) * 2004-06-03 2008-06-10 Козан Байосайенсиз Инкорпорейтед (Us) Соединения лептомицина
WO2007014423A1 (en) * 2005-08-02 2007-02-08 Medvet Science Pty, Ltd. Exercise apparatus
ATE522514T1 (de) 2006-06-16 2011-09-15 Pharma Mar Sa Dihydropyran-2-onverbindungen mit antitumorwirkung
BRPI0821116B8 (pt) 2007-12-20 2021-05-25 Pharma Mar Sa composto, composição farmacêutica que o contem, uso deste e processo para a preparação do mesmo

Also Published As

Publication number Publication date
SI2231590T1 (sl) 2012-10-30
JP2011506575A (ja) 2011-03-03
EP2231633B1 (de) 2013-10-30
NZ597526A (en) 2012-06-29
HRP20140015T1 (hr) 2014-02-14
CA2710087A1 (en) 2009-07-02
NZ586012A (en) 2011-11-25
US20100280108A1 (en) 2010-11-04
UA119963C2 (uk) 2019-09-10
CN101903337A (zh) 2010-12-01
EP2231633A1 (de) 2010-09-29
CN102190643A (zh) 2011-09-21
US20150342972A1 (en) 2015-12-03
EP2231590B1 (de) 2012-03-14
ZA201004018B (en) 2011-12-28
US20150344454A1 (en) 2015-12-03
CA2710087C (en) 2015-06-02
IL229594A0 (en) 2014-01-30
IL206396A (en) 2014-05-28
US20110034549A1 (en) 2011-02-10
ES2578606T3 (es) 2016-07-28
DK2231633T3 (da) 2014-01-20
PT2231633E (pt) 2014-01-20
WO2009080769A1 (en) 2009-07-02
JP5727228B2 (ja) 2015-06-03
IL206397A (en) 2014-01-30
US20120041063A2 (en) 2012-02-16
RU2489429C2 (ru) 2013-08-10
KR101579553B1 (ko) 2015-12-22
AU2008341671A1 (en) 2009-07-02
RU2013112003A (ru) 2014-08-20
JP5529038B2 (ja) 2014-06-25
DK2231590T3 (da) 2012-07-09
HK1147990A1 (en) 2011-08-26
US9827257B2 (en) 2017-11-28
CA2715203A1 (en) 2009-07-02
KR101639772B1 (ko) 2016-07-15
US9187445B2 (en) 2015-11-17
JP2014133752A (ja) 2014-07-24
IL206397A0 (en) 2010-12-30
KR20100125226A (ko) 2010-11-30
RU2528393C1 (ru) 2014-09-20
UA106967C2 (uk) 2014-11-10
IL229594A (en) 2016-02-29
HK1180678A1 (en) 2013-10-25
AU2008341670A1 (en) 2009-07-02
AU2008341670B2 (en) 2012-04-19
CN101903367A (zh) 2010-12-01
KR20100100979A (ko) 2010-09-15
SG170778A1 (en) 2011-05-30
BRPI0821114B1 (pt) 2021-09-08
PT2231590E (pt) 2012-06-25
SI2231633T1 (sl) 2014-02-28
BRPI0821114B8 (pt) 2021-11-09
MX2010006795A (es) 2010-10-26
BRPI0821116B1 (pt) 2020-02-18
EP2231590B9 (de) 2012-08-15
CN102174058A (zh) 2011-09-07
MY164533A (en) 2017-12-29
CA2715203C (en) 2015-09-08
JP2011506578A (ja) 2011-03-03
ZA201106371B (en) 2013-05-29
EP2597091A1 (de) 2013-05-29
BRPI0821116A2 (pt) 2015-08-11
BRPI0821114A2 (pt) 2015-06-16
MX2010006796A (es) 2010-10-26
BRPI0821116B8 (pt) 2021-05-25
KR101541436B1 (ko) 2015-08-03
JP5860088B2 (ja) 2016-02-16
RU2493147C2 (ru) 2013-09-20
MY148651A (en) 2013-05-15
PL2231590T3 (pl) 2012-09-28
HRP20120464T1 (hr) 2012-07-31
ES2442140T3 (es) 2014-02-25
KR20150076265A (ko) 2015-07-06
US9750759B2 (en) 2017-09-05
RS53140B (sr) 2014-06-30
SG170779A1 (en) 2011-05-30
CN101903367B (zh) 2015-08-05
RU2010130180A (ru) 2012-01-27
PL2231633T3 (pl) 2014-03-31
CN101903337B (zh) 2013-12-18
AU2008341671B2 (en) 2012-07-26
ZA201004017B (en) 2011-12-28
EP2231590A1 (de) 2010-09-29
RS52343B (sr) 2012-12-31
UA104281C2 (ru) 2014-01-27
US8710264B2 (en) 2014-04-29
WO2009080761A1 (en) 2009-07-02
HK1147998A1 (en) 2011-08-26
CN102190643B (zh) 2015-02-25
RU2010130253A (ru) 2012-01-27
MY155342A (en) 2015-10-15
EP2597091B1 (de) 2016-04-20
CY1117245T1 (el) 2017-04-05
RU2528393C9 (ru) 2015-01-10
NZ586013A (en) 2012-02-24
ES2384420T3 (es) 2012-07-04
IL206396A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
GEP20125702B (en) Benzimidazole derivatives
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
MX392829B (es) Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales
MY150493A (en) Quinazoline derivatives
UA103625C2 (en) 5-hetrocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enons as herbicides
BRPI0607379B8 (pt) composição farmacêutica de efeito analgésico
EP2578587A4 (de) Pyrazolderivate
IL229594A0 (en) Materials and preparations for the treatment of tumors
MY159479A (en) Herbicides
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
DK2099461T3 (da) LNA Nukleoside Phosphoramidates
NZ593169A (en) Anticancer compounds
BRPI0615141A2 (pt) inibidores pentacìclicos de quinase
NO20092496L (no) Ny terapeutisk anvendelse for behandling av leukemi
WO2010149688A3 (en) Antitumoral compounds
ATE476973T1 (de) Verbindungen mit antitumorwirkung
WO2010009985A3 (en) Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
TW200626588A (en) (Arylamidoaryl)cyanoguanidine compounds
GB0620005D0 (en) Compounds
ATE547414T1 (de) 4-oxadiazolylpiperidinverbindungen und deren verwendung